COTA Genomic Profiling Study Released

11 December, 2019

A retrospective review of the COTA Real World Data (RWD) database was performed to identify patients with pathologically confirmed metastatic colon cancer (mCC) diagnosed between January 1, 2013 and December 1, 2017. Although guidelines recommend molecular testing for patients with mCRC, the current study included patients with mCC and excluded rectal cancer cases. At the time of data extraction, the COTA database included demographic, diagnostic, treatment, and quality-of-care information for patients with colon cancer abstracted from the electronic health records from 23 practices including 258 oncologists in Arkansas, Maryland, Michigan, New Jersey, New York, and Tennessee who contribute data under Business Associate Agreements. All data were de-identified to be compliant with Health Insurance Portability and Accountability Act and Office of Health Promotion Research regulations for purposes of secondary research use. The structure of the COTA database has been reviewed by the Western Institutional Review Board and has been deemed exempt from patient informed consent.

 
Related News
COTA Welcomes Daniel Lane as Vice President for HEOR to Drive Outcomes-Based Research in Oncology
07.25.19
COTA, Inc., a leading precision medicine technology company that uses real-world data to bring clarity to cancer care, has named Daniel Lane as its new Vice President for Health Economics and Outcomes Research (HEOR). Daniel brings extensive experience in leading oncology outcomes research organizations, and leveraging innovative datasets to generate impactful real world evidence (RWE) across multiple healthcare sectors. Combining this with COTA’s expertise and understanding of real-world data will allow the company to better support its partners as they improve access and quality in healthcare. Read Full Release
COTA Signs Research Collaboration Agreement With The U.S. Food and Drug Administration
05.29.19
COTA, Inc., a leading precision medicine technology company that uses real-world evidence to bring clarity to cancer care, today announced it has signed a two-year Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) Information Exchange and Data Transformation (INFORMED) Program, the Agency's data science and technology incubator supporting regulatory science research. This RCA will establish a study protocol with an initial focus on breast cancer, and will provide the FDA with information on the evolving treatment landscape, including insight on treatment variation within defined subpopulations of patients with the disease. As the project advances, the research may expand to other cancer types and explore disease characteristics, treatment patterns, and patient outcomes for the broader application of precision medicine. Read Full Release
COTA Collaborates with Novartis Pharmaceuticals Corporation
03.27.17
Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients. As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will leverage Cota's research-grade, real-world evidence, web-based analysis and visualization tools, and be supported by Cota's medical, data science, and technology experts. Utilizing the real-world evidence and technology platform supplied by Cota is expected to enable Novartis Pharmaceuticals Corporation to accelerate clinical development of new therapies for breast cancer and identify which patients will benefit most. Read Full Release